PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001
TOKYO--(BUSINESS WIRE)--PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor.
'We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor' said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. 'Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in humans as well. Our preclinical animal models (LDL-R KO mice; HoFH model, and high-fat diets induced MASH model mice) have shown that PRD001 lowers blood and liver lipids and suppresses the progression of fatty liver and atherosclerosis with no adverse events. PRD001 has the potential to be the first-in-class effective and safe oral therapy for HoFH patients suffering from no or extremely low LDL receptor activity.'
This FIH Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and the signs of early efficacy (LDL-C lowing effect, and liver fat quantitative value using MRI-PDFF) of PRD001 in adult healthy volunteers. More information can be found at NCT07034183.
About PRD001
PRD001 is a first-in-class, orally available small molecule SOAT2-selective inhibitor. It uniquely controls three key pathways of lipid metabolism; cholesterol synthesis in the liver, cholesterol absorption in the small intestine, and uptake of blood LDL-C with a single drug, leading to a potent reduction in a blood LDL-C level independent of the LDL receptor.
This research and development is supported by Japan Agency for Medical Research and Development (AMED) under Strengthening Program for Pharmaceutical Startup Ecosystem (Project title: " Development of First-in-class oral lipid metabolism regulator PRD001 and POC obtained for lipid metabolism disorder ").
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14 hours ago
- Business Wire
ELV Deadline: Rosen Law Firm Urges Elevance Health, Inc. (NYSE: ELV) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Elevance Health, Inc. (NYSE: ELV) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that, with the Medicaid redetermination process nearly complete, defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in Elevance's guidance for the year. These representations were materially false or misleading. In truth, the redeterminations were causing the acuity and utilization of Elevance's Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs. This shift was occurring to a degree that was not reflected in Elevance's rate negotiations with the states or in its financial guidance for 2024. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Elevance Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Newsweek
a day ago
- Newsweek
Parents Welcome Baby Boy, 3 Months Later Realize Something Is Wrong
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A woman has revisited the moment she began to suspect something wasn't right with her newborn son and the emotional journey that followed as she sought to find answers. Carli Cowie from Moray in Scotland, took to her TikTok account, Carlirose33, to share pictures of Noah from when he was born on November 3, 2018 and in the blissful days that followed. "The best day of my life," Cowie wrote alongside the images. "I couldn't stop staring at him. I couldn't believe this beautiful baby was ours. Our hearts were so full of love." By the time Noah's six-week check-up rolled around, everything seemed to be on track. "He was hitting milestones," Cowie said. But by 12 weeks, Cowie and her husband had started to notice "something wasn't right." Cowie told Newsweek: "He wasn't making eye contact with us, wasn't following toys and his eyes were wobbling." Carli first noticed an issue with Noah's eyes when he was just 12 weeks old. Carli first noticed an issue with Noah's eyes when he was just 12 weeks old. TikTok/carlirose33 They made an appointment for Noah to see their doctor, who then referred them on to an ophthalmologist. At this point, there were concerns Noah could have retinoblastoma, a rare type of cancer affecting the retina. Read more Woman remembers one thing dad "regretted"—30 years later she makes it right Woman remembers one thing dad "regretted"—30 years later she makes it right In order to find out if this was the case, doctors needed to dilate his pupils to check. All this time, Cowie and her husband were left facing an anxious wait for answers. "We were so worried and didn't know what the outcome was going to be," she said. She estimates it took three months from that initial doctor's appointment, for them to get an understanding of Noah's condition. Doctors suspected Noah had been born with optic nerve hypoplasia, meaning his optic nerves were under-developed. The "wobbling" movement his eyes made was also thought to be a result of nystagmus, an involuntary eye movement condition that further reduces or limits vision. A delayed MRI scan eventually confirmed the heartbreaking diagnosis: Noah was blind. His parents were left in shock at the news. "We were devastated and in disbelief that this was happening to our baby," Cowie said. "We initially thought it wouldn't be something as serious as what it was, we thought he'd maybe need glasses or something along those lines." Though Cowie was rocked by the news, she managed to stay strong, with the support of her husband and family, knowing it was important to maintain a happy household for Noah's sake. "I didn't want Noah to pick up if we were upset so I always tried to be in high spirits for him," she said. "Although he was blind I kept reminding myself that he was healthy and we were grateful for that." Noah underwent regular check-ups in the years that followed with doctors careful to monitor that his weight and height was within the normal range. "If the tests weren't in normal range he would have been put on growth hormone injections until he was 18," Cowie said. Thankfully, for Noah, that wasn't needed and by the time he turned 4, he was fully discharged and ready to his way as a blind child out in the world. He's not alone in that respect. In the U.S., the CDC estimates nearly 3 percent of children under the age of 18 have blindness or vision impairment. Noah Cowie is 6 and thriving now. Noah Cowie is 6 and thriving now. TikTok/carlirose33 It's a life that comes with its own unique challenges for his mom and dad. "One of the biggest I would say is his safety and making sure there is nothing in his way or lying out for him to trip over or bump into," Cowie said. But it is one that Noah, now 6, is thriving in, with a little help from mom, dad and his two-year-old sister Ocean. "He's doing really well. Noah is always keen to try new things and we are amazed with how well he gets on," Callie said. "He's a clever boy and enjoys learning. He's at the early stages of learning braille and learning to use his cane with support." Callie's TikTok video, chronicling their journey with Noah went viral, amassing over 640,000 views since being posted earlier this month. She's incredibly proud of her son and hopes this video and others like it help any families who may be going through similar situations with a young child. Noah's story isn't one of heartbreak, it's one of hope. "I wanted to show everyone how amazing he is," Callie said. "Being blind hasn't stopped him from doing anything."
Business Wire
a day ago
- Business Wire
Rocket Lab Completes Record Launch Turnaround From Launch Complex 1, Successfully Deploys 68 th Electron Mission
MAHIA, New Zealand--(BUSINESS WIRE)--Rocket Lab Corporation (Nasdaq: RKLB) ('Rocket Lab' or 'the Company'), a global leader in launch services and space systems, today successfully launched its 68th Electron rocket to deploy a single satellite to space for a confidential commercial customer. The mission was the second of two launches from the same launch site in less than 48 hours, a new launch record for the Company as it continues to deliver dedicated, repeatable and reliable access to space for satellite operators. The 'Symphony In The Stars' mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand on June 28 th (7:08 p.m./07:08 UTC) to deploy a single spacecraft to a 650km circular Earth orbit. The mission was the first of two dedicated launches for the new customer on Electron booked less than four months ago, with a second mission scheduled before the end of 2025. Rocket Lab has now completed four launches in June for commercial satellite constellation operators, underscoring Electron's consistent performance and rapid deployment capabilities as the world's leading small launcher: the 'Full Stream Ahead' mission on June 3 rd; 'The Mountain God Guards' mission on June 11 th; 'Get The Hawk Outta Here' launched on June 26 th UTC, and today's 'Symphony In The Stars' mission. Rocket Lab Founder and CEO, Sir Peter Beck, says: 'Electron has demonstrated once again that it is the gold standard for responsive and reliable space access for small satellites. The future of space is built on proven performance, and Electron continues to deliver against a stacked launch manifest this year. Congratulations to the team on achieving its fastest launch turnaround yet between two missions from Launch Complex 1. This launch was also a quick-turn mission to meet our customer's mission requirements, and we're looking forward to doing it again later this year.' 'Symphony In The Stars' was Rocket Lab's tenth Electron mission of 2025 and its 68th launch overall. With 100% mission success so far this year, Electron continues to deliver reliable deployment amid an increasing launch cadence and rapid contract-to-launch timelines. Launch images: About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered over 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words 'believe,' 'may,' 'will,' 'estimate,' 'potential,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'strategy,' 'future,' 'could,' 'would,' 'project,' 'plan,' 'target,' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'), accessible on the SEC's website at and the Investor Relations section of our website at which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
